OpenBit ResearchOpenBit
中文

What's driving Capricor Therapeutics (CAPR)

Compiled from the engine's research, source claims and public filings in this dossier. Each has its own data date, listed below.

Research summary

Capricor Cash Preservation and Strategic Reset

Why it matters now

Further cash depletion and elevated operating expenses would pressure Capricor's liquidity and financing capacity.

Next checkpoint

Capricor special committee initial plan (expected 2026-10-05) · Watch: A special committee filing or company disclosure presents its initial plan addressing asset sales, partnerships, restructuring, or operating-wind-down decisions.

What would break the thesis

Cash use accelerates without credible preservation measures or a viable strategic path before regulatory resolution.

Research drivers

  • Capricor Cash Preservation and Strategic Reset

    Bearish · Active · Updated

    The three-month delay to the Deramiocel regulatory decision extends the period in which Capricor must preserve liquidity and execute a strategic reset.

  • Capricor Deramiocel BLA Review and Refined Indication

    Mixed · Active · Updated

    The FDA accepted the major amendment and did not issue a Complete Response Letter, but the prior advisory committee effectiveness vote and extended review leave support for the refined indication unresolved.

Source claims

Source labels are as recorded in our data. The dossier does not include links to the originals, so these are not verified quotations.

  • The upper-limb functional-preservation findings directly support the core efficacy metrics under FDA review for Capricor's amended Biologics License Application.

    Relayed by: Benzinga · Event date on record:

  • The HOPE-3 data demonstrated that deramiocel sharply slowed the decline of upper-limb function compared with placebo over the two-year evaluation period.

    Relayed by: Benzinga · Event date on record:

  • The FDA's Center for Biologics Evaluation and Research accepted the amendment for review, citing significant unmet medical need in Duchenne muscular dystrophy.

    Relayed by: Benzinga · Event date on record:

  • Capricor Therapeutics submitted a BLA amendment containing 24-month open-label extension data from its pivotal Phase 3 HOPE-3 study and additional robustness analyses, requesting FDA review in support of a refined proposed indicat

    Relayed by: Benzinga · Event date on record:

  • The FDA classified the submission as a major amendment and extended the PDUFA target action date by three months to allow additional review time.

    Relayed by: Benzinga · Event date on record:

Related sectors

Biotech

Filed holders

This dossier has no filed holders to show. That does not mean no institution holds it.